Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Luqa Acquires China Rights to Next-Gen Dermal Filler

publication date: Jan 11, 2016
Luqa Pharmaceuticals, a China dermatological in-licensing company, has acquired greater China rights to a next-generation dermal filler. Luqa did not identify the product or the maker, but did say the filler would be available in a range of formats. According to Luqa, the new dermal product is a first-in-class dermal filler that works by first filling skin wrinkles, and then stimulating the production of collagen. Luqa will be responsible for development, sales, marketing and distribution in China, Hong Kong and Macau with a launch expected during the first half of 2016. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital